For non-transplant patients, however, the utilization of anti-PD-1/PD-L1 immune checkpoint blockade (ICB) therapies has substantially improved survival outcomes compared to TKIs in patients with metastatic HCC. Here, CD274 is linked to hepatocellular carcinoma.